Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance

Young June Kim, Hal Broxmeyer

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Umbilical cord blood (UCB) is a source of primitive hematopoietic stem (HSC) and progenitor cells, that served as an alternative to bone marrow (BM) for effective transplantation therapy. Success of HSC transplantation (HSCT) is limited in part by graft-versus-host disease (GVHD), graft rejection and delayed immune reconstitution, which all relate to immunological complications. GVHD after UCB transplantation is lower compared to that of BM HSCT. This may relate to the tolerogenic nature of T cells, mononuclear cells (MNCs) and especially immune regulatory cells existing in UCB. UCB contains limiting numbers of HSC or CD34 + cell dose for adult patients resulting in delayed engraftment after UCB transplantation (UCBT). This needs to be improved for optimal transplantation outcomes. Approaches have been undertaken to promote HSC engraftment, including co-infusion of multiple units of UCB cells. These new methods however added additional immunological complications. Herein, we describe current knowledge on features of UCB immune cells, including regulatory T cells (Tregs) and mesenchymal stem/stromal cells (MSCs) and their potential future usage to reduce GVHD.

Original languageEnglish
Pages (from-to)112-126
Number of pages15
JournalCritical Reviews in Oncology/Hematology
Volume79
Issue number2
DOIs
StatePublished - Aug 2011

Fingerprint

Transplantation Tolerance
Fetal Blood
Graft vs Host Disease
Transplantation
Hematopoietic Stem Cells
Bone Marrow Transplantation
Mesenchymal Stromal Cells
Blood Cells
Graft Rejection
Regulatory T-Lymphocytes
T-Lymphocytes

Keywords

  • Cord blood transplantation
  • Dendritic cells
  • Mesenchymal stromal/stem cells
  • Natural killer cells
  • Regulatory T cells
  • T-lymphocytes
  • Transplantation tolerance

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. / Kim, Young June; Broxmeyer, Hal.

In: Critical Reviews in Oncology/Hematology, Vol. 79, No. 2, 08.2011, p. 112-126.

Research output: Contribution to journalArticle

@article{9de618a6eb38470a8cf8522b60a7a241,
title = "Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance",
abstract = "Umbilical cord blood (UCB) is a source of primitive hematopoietic stem (HSC) and progenitor cells, that served as an alternative to bone marrow (BM) for effective transplantation therapy. Success of HSC transplantation (HSCT) is limited in part by graft-versus-host disease (GVHD), graft rejection and delayed immune reconstitution, which all relate to immunological complications. GVHD after UCB transplantation is lower compared to that of BM HSCT. This may relate to the tolerogenic nature of T cells, mononuclear cells (MNCs) and especially immune regulatory cells existing in UCB. UCB contains limiting numbers of HSC or CD34 + cell dose for adult patients resulting in delayed engraftment after UCB transplantation (UCBT). This needs to be improved for optimal transplantation outcomes. Approaches have been undertaken to promote HSC engraftment, including co-infusion of multiple units of UCB cells. These new methods however added additional immunological complications. Herein, we describe current knowledge on features of UCB immune cells, including regulatory T cells (Tregs) and mesenchymal stem/stromal cells (MSCs) and their potential future usage to reduce GVHD.",
keywords = "Cord blood transplantation, Dendritic cells, Mesenchymal stromal/stem cells, Natural killer cells, Regulatory T cells, T-lymphocytes, Transplantation tolerance",
author = "Kim, {Young June} and Hal Broxmeyer",
year = "2011",
month = "8",
doi = "10.1016/j.critrevonc.2010.07.009",
language = "English",
volume = "79",
pages = "112--126",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance

AU - Kim, Young June

AU - Broxmeyer, Hal

PY - 2011/8

Y1 - 2011/8

N2 - Umbilical cord blood (UCB) is a source of primitive hematopoietic stem (HSC) and progenitor cells, that served as an alternative to bone marrow (BM) for effective transplantation therapy. Success of HSC transplantation (HSCT) is limited in part by graft-versus-host disease (GVHD), graft rejection and delayed immune reconstitution, which all relate to immunological complications. GVHD after UCB transplantation is lower compared to that of BM HSCT. This may relate to the tolerogenic nature of T cells, mononuclear cells (MNCs) and especially immune regulatory cells existing in UCB. UCB contains limiting numbers of HSC or CD34 + cell dose for adult patients resulting in delayed engraftment after UCB transplantation (UCBT). This needs to be improved for optimal transplantation outcomes. Approaches have been undertaken to promote HSC engraftment, including co-infusion of multiple units of UCB cells. These new methods however added additional immunological complications. Herein, we describe current knowledge on features of UCB immune cells, including regulatory T cells (Tregs) and mesenchymal stem/stromal cells (MSCs) and their potential future usage to reduce GVHD.

AB - Umbilical cord blood (UCB) is a source of primitive hematopoietic stem (HSC) and progenitor cells, that served as an alternative to bone marrow (BM) for effective transplantation therapy. Success of HSC transplantation (HSCT) is limited in part by graft-versus-host disease (GVHD), graft rejection and delayed immune reconstitution, which all relate to immunological complications. GVHD after UCB transplantation is lower compared to that of BM HSCT. This may relate to the tolerogenic nature of T cells, mononuclear cells (MNCs) and especially immune regulatory cells existing in UCB. UCB contains limiting numbers of HSC or CD34 + cell dose for adult patients resulting in delayed engraftment after UCB transplantation (UCBT). This needs to be improved for optimal transplantation outcomes. Approaches have been undertaken to promote HSC engraftment, including co-infusion of multiple units of UCB cells. These new methods however added additional immunological complications. Herein, we describe current knowledge on features of UCB immune cells, including regulatory T cells (Tregs) and mesenchymal stem/stromal cells (MSCs) and their potential future usage to reduce GVHD.

KW - Cord blood transplantation

KW - Dendritic cells

KW - Mesenchymal stromal/stem cells

KW - Natural killer cells

KW - Regulatory T cells

KW - T-lymphocytes

KW - Transplantation tolerance

UR - http://www.scopus.com/inward/record.url?scp=79960155788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960155788&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2010.07.009

DO - 10.1016/j.critrevonc.2010.07.009

M3 - Article

VL - 79

SP - 112

EP - 126

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -